Option chain shows key data for Rallybio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Rallybio.

Rallybio (NASDAQ:RLYB) Stock, Option Chain

Rallybio

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Marion,-,Circa,October,2021:,General,Motors,Logo,And,Signage

News

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

IRWD

MBLY

RLYB

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts

Markets

HCAT

TECH

This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

BZ_briefs

Biotech

Health Care

Movers

General

Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio Corp

Press Releases

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Abpro Hldgs

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HOOKIPA Pharma

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Kairos Pharma

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Polyrizon

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

Evercore ISI Group

JMP Securities

Wedbush

Jefferies

Comments

Rallybio

Rallybio (RLYB) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell